Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adebrelimab - Atridia

Next Previous
X
Search
Drug Profile

Adebrelimab - Atridia

Alternative Names: HTI-1088; HTI-1316; SHR 1316

Latest Information Update: 04 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atridia; Jiangsu Hengrui Medicine Co.; Shandong Cancer Hospital and Institute
  • Developer Atridia; Jiangsu Hengrui Medicine Co.; Shandong Cancer Hospital and Institute; Sheng Jing Hospital; Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Small cell lung cancer
  • Phase III Non-small cell lung cancer
  • Phase II Cervical cancer; Oesophageal cancer
  • Phase I Solid tumours
  • Clinical Phase Unknown Breast cancer
  • No development reported Cancer; Haematological malignancies

Most Recent Events

  • 19 Sep 2024 Jiangsu HengRui Medicine terminates a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater, Combination therapy) in China (Parenteral) due to R&D strategy adjustment (NCT05048134)
  • 20 Jun 2024 Shanghai Hengrui Pharmaceutical initiates phase-I/II clinical trials in Oesophageal cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV) (NCT06474468)
  • 31 May 2024 Efficacy and adverse events data from a phase II trial in Small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top